EPS for Birks Group (BGI) Expected At $0.00, VITALITY BIOPHARMA (VBIO) Shorts Increased By 192.62%

June 19, 2017 - By Henry Gaston

Analysts expect Birks Group Inc (NYSEMKT:BGI) to report $0.00 EPS on July, 4. The stock decreased 6.90% or $0.1 on June 16, reaching $1.35. About shares traded. Birks Group Inc (NYSEMKT:BGI) has risen 188.30% since June 19, 2016 and is uptrending. It has outperformed by 171.60% the S&P500.

VITALITY BIOPHARMA INCORPORATED (OTCMKTS:VBIO) had an increase of 192.62% in short interest. VBIO’s SI was 392,400 shares in June as released by FINRA. Its up 192.62% from 134,100 shares previously. With 709,200 avg volume, 1 days are for VITALITY BIOPHARMA INCORPORATED (OTCMKTS:VBIO)’s short sellers to cover VBIO’s short positions. The stock increased 0.92% or $0.02 on June 16, reaching $2.19. About 88,268 shares traded. Vitality Biopharma Inc (OTCMKTS:VBIO) has 0.00% since June 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Birks Group Inc is a Canada-based company engaged in designing, developing, making and retail of jewelry, timepieces and gifts. The company has market cap of $23.08 million. The Firm operates through two divisions: Retail and Other. It has a 9.26 P/E ratio. The Company’s Retail segment consists of all its retail activities in the United States and Canada on a combined basis.

Vitality Biopharma, Inc., formerly Stevia First Corp., is engaged in the development of cannabinoid prodrug pharmaceuticals. The company has market cap of $42.83 million. The Firm unlocks the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. It currently has negative earnings. The Company’s product pipeline includes cannabosides, VITA-100 and VITA-210.